to develop stenosis, whereas valves with more redundant tissue usually develop valvular incompetence (3). The incidence of aortic stenosis complicating BAV in an autopsy series ranges from 15% to 75% (1) . Progression of BAV stenosis is age related, with fibrosis beginning in the second decade and calcification progressing significantly after the fourth decade. Among octogenarians and nonagenarians undergoing surgical aortic valve replacement (AVR), 22% and 18%, respectively, were found to have BAV (5) . Bicuspid aortopathy (i.e., dilation of any or all segments of the proximal aorta from the aortic root to the aortic arch) is the most common nonvalvular finding and is present in up to 50% of affected persons (2, 6) . Abnormal dilation of the ascending aorta is secondary to abnormalities of the aortic media and becomes of surgical interest when the aortic diameter exceeds 4.5 cm (6). Aortic media changes are present independent of whether the valve is functionally normal, stenotic, or incompetent.
Ascending aorta pathology is an expression of the genetic basis of BAV and may justify a more complex surgical treatment (2) . All these differences between BAV and senile aortic valve stenosis affecting tricuspid aortic valves may justify the reason why BAV stenosis has been considered a contraindication for transcatheter AVR (TAVR) in most studies. The specific concerns regarding TAVR for BAV include:
1. An elliptically shaped annulus that may impair valve positioning and sealing. The main conclusions we can draw from this important study are:
1. TAVR with first-generation aortic valves is feasible in selected patients with BAV (device success of 90%, 1-year mortality of 17.5%, 30-day incidence of stroke of 2%).
2. The incidence of significant aortic regurgitation is high at 28.4% (9% in the CoreValve pivotal trial and 12.2% in the PARTNER 1A trial).
3. When accurate sizing is performed using MSCT, the incidence of aortic regurgitation decreases to 17%. 
